Short Bowel Syndrome Market Size and Share Analysis, Leading Companies, Clinical Assessment of the Pipeline Therapies, and Epidemiology Forecast

 Breaking News
  • No posts were found

Short Bowel Syndrome Market Size and Share Analysis, Leading Companies, Clinical Assessment of the Pipeline Therapies, and Epidemiology Forecast

August 16
14:51 2021
Short Bowel Syndrome Market Size and Share Analysis, Leading Companies, Clinical Assessment of the Pipeline Therapies, and Epidemiology Forecast
Delveinsight Business Research LLP

DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Short Bowel Syndrome Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Short Bowel Syndrome Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Short Bowel Syndrome Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Short Bowel Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 Short Bowel Syndrome Market

Short Bowel Syndrome Disease Overview

Short bowel syndrome (SBS) is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. SBS is generally broken down into individuals in whom the disorder is acquired during life and newborns in which the disorder is present at birth (congenital). Acquired short bowel syndrome is more common than the congenital form of the disorder.

The manifestations of intestinal resection and SBS are a result of; the loss of intestinal absorption surface; the loss of specific sites of absorption; a decrease in the production of intestinal hormones; and the loss of the ileocecal valve.

Short Bowel Syndrome Market Key Facts

  • As per the data published in Crohn’s & Colitis Foundation of America, approximately 10,000–20,000 people suffer from Short Bowel Syndrome in the United States.

  • As per the study conducted by Websky et al., titled “Short bowel syndrome in Germany. Estimated prevalence and standard of care”, the prevalence of Short Bowel Syndrome (SBS) in Germany is 34 per million inhabitants.

  • According to the American Pediatric Surgical Association, the most common cause of Short Bowel Syndrome (SBS) in infants and babies is necrotizing enterocolitis (NEC) which accounts for up to 40% of SBS patients.

  • According to the European Medicines Agency, SBS affected not more than 0.35 in 10,000 people in the European Union (EU). 

Get FREE sample copy at:

Key Benefits of Short Bowel Syndrome Market Report

  • The market report provides an in-depth analysis of Short Bowel Syndrome Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Short Bowel Syndrome Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Short Bowel Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Short Bowel Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Short Bowel Syndrome Market 

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Short Bowel Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Short Bowel Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Short Bowel Syndrome Therapeutics Market Assessment

Short Bowel Syndrome Epidemiology

The epidemiology section covers insights about the historical and current Short Bowel Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched in the market during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Short Bowel Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Some of the key companies in the Short Bowel Syndrome (SBS) market include:

  • Zealand Pharma

  • PhaseBio Pharmaceuticals 

  • VectivBio

  • NPS Pharmaceuticals (Acquired by Shire Plc.)

And many others.

Short Bowel Syndrome Therapies covered in the report include:

  • Gattex (teduglutide)

  • Glepaglutide

  • Apraglutide

And many others.

Table of Content

1. Key Insights

2. Executive Summary 

3. Short Bowel Syndrome Competitive Intelligence Analysis

4. Short Bowel Syndrome Market Overview at a Glance

5. Short Bowel Syndrome Disease Background and Overview

6. Short Bowel Syndrome Patient Journey

7. Short Bowel Syndrome Epidemiology and Patient Population

8. Short Bowel Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Short Bowel Syndrome Unmet Needs

10. Key Endpoints of Short Bowel Syndrome Treatment

11. Short Bowel Syndrome Marketed Products

12. Short Bowel Syndrome Emerging Therapies

13. Short Bowel Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Short Bowel Syndrome Market Outlook (7 major markets)

16. Short Bowel Syndrome Access and Reimbursement Overview

17. KOL Views on the Short Bowel Syndrome Market.

18. Short Bowel Syndrome Market Drivers

19. Short Bowel Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Short Bowel Syndrome Pipeline Insights

Short Bowel Syndrome Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Short Bowel Syndrome market.

Healthcare Blogs

Virtual Clinical Trials 

The virtual clinical trial is one of the growing concepts in the healthcare sector getting significant attention owing to various benefits that they bring forth with them as compared to the conventional model. To get an early advantage and to capture the market share, tech providers such as Science 37, Syneos Health, Flatiron Health, Deep 6 AI, SubjectWell, Tempus Labs, Altos Solutions, ObvioHealth, Clinpalidor, VirTrial, Lightship, Medable, PAREXEL International, Medidata Solutions, PRA Health Sciences, Curavit, and several others are actively engaged in the virtual clinical trials segment. For more details, visit: Virtual Clinical Trials Benefits and Challenges

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles